Phase 2 Study with Safety Run-in of PD-1 Inhibitor and IgG4 SIRPα-Fc Fusion Protein (TTI-622) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
Latest Information Update: 20 Sep 2024
Price :
$35 *
At a glance
- Drugs Maplirpacept (Primary) ; Ontorpacept (Primary) ; Pembrolizumab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 13 Sep 2024 Planned number of patients changed from 62 to 41.
- 20 Apr 2023 Status changed from not yet recruiting to recruiting.
- 01 Feb 2023 Planned initiation date changed from 15 Jan 2023 to 15 Mar 2023.